ESMO 2023 | Professor Zhongsheng Tong: New Trop-2 ADC Brings New Hope for HR+/HER2- Advanced Breast Cancer Patients

ESMO 2023 | Professor Zhongsheng Tong: New Trop-2 ADC Brings New Hope for HR+/HER2- Advanced Breast Cancer Patients

According to the cancer burden data released by the World Health Organization, hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 60%. The treatment strategies and survival benefits for first-line and subsequent-line therapy for HR+/HER2- advanced breast cancer have been a hot topic. The TROPION-Breast01 study data, unveiling the promising results of the new ADC drug Dato-DXd in the field of HR+/HER2- advanced breast cancer, were disclosed at this year's ESMO conference. Professor Zhongsheng Tong from Tianjin Medical University Cancer Hospital, a prominent figure in the field, interprets the findings for Oncology Frontier.
ESMO China Voice | Professor Xiaohua Wu’s Team Presents Two LBA Studies at ESMO, Adding Chinese Solutions to Gynecological Cancer Treatment

ESMO China Voice | Professor Xiaohua Wu’s Team Presents Two LBA Studies at ESMO, Adding Chinese Solutions to Gynecological Cancer Treatment

On October 20, the 2023 European Society for Medical Oncology (ESMO) Congress officially opened in Madrid, Spain. As one of the most influential global oncology conferences, top experts from around the world gathered to discuss and share the latest international research findings and cancer treatment technologies. Professor Xiaohua Wu's team from Fudan University Affiliated Cancer Hospital presented two significant studies at the ESMO 2023 Late-breaking Abstract (LBA) session, providing important references for clinical practice. "Oncology Frontier" had the privilege of inviting Professor Xiaohua Wu to share the research findings on-site.
ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma

ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma

Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role in the treatment of cholangiocarcinoma (CCA) with FGFR alterations after chemotherapy. However, disease progression occurs after 6-8 months. Secondary multiclonal mutations in the FGFR2 kinase domain represent a notable acquired resistance mechanism. Tinengotinib is identified as a novel FGFRi with high efficacy against various FGFR2 kinase domain mutations and has shown promising clinical results in CCA patients previously treated with FGFRi. This study presents summary data from three trials.
AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.
AASLD2023 | Unveiling the Four Prestigious “Distinguished Awards” on the First Day of the Conference!

AASLD2023 | Unveiling the Four Prestigious “Distinguished Awards” on the First Day of the Conference!

From November 10th to 14th, the grand finale of the international hepatology scene, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, unfolded in Boston, USA. AASLD, in its annual tradition, awarded the "Distinguished Awards" during the conference to honor peers who have made significant strides in the field of hepatology. The recipients of the coveted 2023 "Distinguished Awards" were announced on the conference's inaugural day (local time, November 10th).
Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.
AASLD 2023: 17 Must-See Studies

AASLD 2023: 17 Must-See Studies

From November 10th to 14th, the annualHepatology Digest  conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.
Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for neoadjuvant treatment in resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No.: LBA73). The mid-term analysis showed a clinically and statistically significant improvement in the pathological complete response (pCR) rate, making MATTERHORN the first neoadjuvant Phase III immunotherapy regimen in gastric cancer to show positive results. "Tumor Outlook" invited Professor Liang Han from Tianjin Medical University Cancer Hospital to provide an in-depth interpretation of the study.
ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

Metastatic sarcoma presents a formidable challenge in the realm of cancer treatment. The sheer diversity of sarcoma subtypes and the necessity of tailoring treatments to each specific histology makes the quest for effective therapies all the more complex. In this article, we delve deeper into the current landscape of advancements and challenges in the treatment of metastatic sarcoma, guided by the insights of Professor Stacchiotti.